IN2012DN02736A - "compounds and compositions as tlr activity modulators" - Google Patents

"compounds and compositions as tlr activity modulators" Download PDF

Info

Publication number
IN2012DN02736A
IN2012DN02736A IN2736/DELNP/2012A IN2736DEN2012A IN2012DN02736A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A IN 2736DEN2012 A IN2736DEN2012 A IN 2736DEN2012A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A
Authority
IN
India
Prior art keywords
compounds
compositions
activity modulators
tlr activity
tlr
Prior art date
Application number
IN2736/DELNP/2012A
Inventor
Alex Cortez
Yongkai Li
Manmohan Singh
David Skibinski
Tom Yao Hsiang Wu
Kathy Yue
Xiaoyue Zhang
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US23921709P priority Critical
Priority to US20090239217P priority
Priority to US20100874153 priority
Priority to PCT/US2010/047587 priority patent/WO2011049677A1/en
Priority to WO2010US47587 priority
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IN2012DN02736A publication Critical patent/IN2012DN02736A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
IN2736/DELNP/2012A 2009-09-02 2012-03-29 "compounds and compositions as tlr activity modulators" IN2012DN02736A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US23921709P true 2009-09-02 2009-09-02
US20090239217P 2009-09-02
US20100874153 2010-09-01
PCT/US2010/047587 WO2011049677A1 (en) 2009-09-02 2010-09-01 Compounds and compositions as tlr activity modulators
WO2010US47587 2010-09-01

Publications (1)

Publication Number Publication Date
IN2012DN02736A true IN2012DN02736A (en) 2015-09-11

Family

ID=43625759

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2736/DELNP/2012A IN2012DN02736A (en) 2009-09-02 2012-03-29 "compounds and compositions as tlr activity modulators"

Country Status (25)

Country Link
US (2) US9045470B2 (en)
EP (1) EP2473508B1 (en)
JP (1) JP5525614B2 (en)
CN (1) CN102712636B (en)
AR (1) AR078153A1 (en)
AU (1) AU2010308524B2 (en)
BR (1) BR112012004696A2 (en)
CA (1) CA2772657C (en)
CY (1) CY1119618T1 (en)
DK (1) DK2473508T3 (en)
EA (1) EA020962B1 (en)
ES (1) ES2627669T3 (en)
HR (1) HRP20170707T1 (en)
HU (1) HUE032323T2 (en)
IN (1) IN2012DN02736A (en)
JO (1) JO3257B1 (en)
LT (1) LT2473508T (en)
MX (1) MX2012002654A (en)
PE (1) PE11562012A1 (en)
PL (1) PL2473508T3 (en)
PT (1) PT2473508T (en)
SI (1) SI2473508T1 (en)
TW (1) TWI445708B (en)
UY (1) UY32874A (en)
WO (1) WO2011049677A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
EP2459216B1 (en) 2009-09-02 2013-10-30 Novartis AG Immunogenic compositions including tlr activity modulators
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
BR112012014624A8 (en) 2009-12-15 2017-12-26 Novartis Ag homogeneous suspension of immunopotentiation compounds and uses of these
EP2402028A1 (en) * 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing and treating type 1 diabetes (II)
EA201390341A1 (en) 2010-09-01 2013-08-30 Новартис Аг Adsorption of immunote potentiators on insoluble salts of metals
BR112013022397A2 (en) 2011-03-02 2017-09-26 Derek O’Hagan vaccines combined with lower doses of antigen and / or adjuvant
WO2012125942A1 (en) * 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
CA2847204A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
CN104519910B (en) * 2012-03-07 2017-05-03 诺华股份有限公司 S. pneumoniae antigen adjuvant formulations containing
JP6325986B2 (en) * 2012-03-07 2018-05-16 ノバルティス アーゲー Immunologically useful arginine salt
CA2866426A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of rabies virus immunogens
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
CN104736563A (en) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
CN103845731B (en) * 2012-12-05 2015-12-02 复旦大学 Application of Anti st2 / il-1r4 antibody in the manufacture of a medicament in the prevention and treatment of pruritus
MX2015008847A (en) * 2013-01-10 2015-10-30 Novartis Ag Influenza virus immunogenic compositions and uses thereof.
US9827190B2 (en) * 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
CA2911296A1 (en) 2013-05-10 2014-11-13 Wayne Volkmuth Avoiding narcolepsy risk in influenza vaccines
CN104338129B (en) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 The use of rapamycin and a method for preparing a vaccine adjuvant
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag Compounds and compositions for the treatment of solid tumors by intratumoral administration

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag A process for the preparation of membrane proteins from Neisseria meningitidis and these vaccine containing
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2000511769A (en) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション Novel compounds
JP2000508178A (en) 1996-05-14 2000-07-04 スミスクライン・ビーチャム・コーポレイション Novel compounds
ES2277362T5 (en) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DE69738472D1 (en) 1997-08-21 2008-03-06 Nederlanden Staat New mutant of the gram-negative mucosal bacteria and their use as vaccines
JPH1180156A (en) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1-(substitutedaryl)alkyl-1h-imidazopyridin-4-amine derivative
EP2278006A3 (en) 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
EP2319931A1 (en) 1997-11-26 2011-05-11 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
EP2278011A3 (en) 1998-01-14 2012-03-07 Novartis Vaccines and Diagnostics S.r.l. Neisseria meningitidis antigens
AU770378B2 (en) 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
EP1144640A3 (en) 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
JP2002531055A (en) 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド Protein and nucleic acid molecules of S. pneumoniae
WO2000012689A1 (en) 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
AT422368T (en) 1998-08-31 2009-02-15 Inhibitex Inc Multicomponent vaccines against staphylococcus aureus
CA2346713A1 (en) 1998-10-09 2000-04-20 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
CN1198932C (en) 1999-03-26 2005-04-27 科特克斯(Om)有限公司 Streptococcus pneumoniae antigens
ES2360296T3 (en) 1999-06-10 2011-06-02 Human Genome Sciences, Inc. Vaccines and proteins setreptococcus pneumoniae.
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
DK2270030T3 (en) 2000-02-28 2012-08-13 Novartis Vaccines & Diagnostic Heterologous expression of Neisseria proteins
AU4934501A (en) 2000-03-21 2001-10-03 Elitra Pharmaceuticals Inc Identification of essential genes in prokaryotes
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
CA2407455A1 (en) 2000-04-27 2001-11-01 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningitidis serogroup and fremgangsmÕte the preparation thereof
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
EP2166019A3 (en) 2000-07-03 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Immunisation against Chlamydia Pneumoniae
AU8764501A (en) 2000-07-20 2002-02-05 Hansa Medical Ab Protein
MXPA03000822A (en) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis.
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU9579501A (en) 2000-10-26 2002-05-06 Imp College Innovations Ltd Streptococcal genes
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
AT410798B (en) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh A method for identification, isolation and production of antigens to a specific pathogen
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
CA2447599C (en) 2001-05-18 2015-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
JP4424984B2 (en) 2001-06-15 2010-03-03 インヒビテックス インコーポレーテッド Recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus, cross-reactive monoclonal and polyclonal antibodies
JP4404627B2 (en) 2001-08-02 2010-01-27 バイオシネクサス・インコーポレイテッド Antigenic polypeptide
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AT406912T (en) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunization against chlamydia tracheomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275125A3 (en) 2002-04-02 2011-03-09 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
EP1511768B1 (en) 2002-06-11 2007-04-11 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
KR20050039839A (en) 2002-08-02 2005-04-29 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2498847C (en) 2002-09-13 2014-10-28 Chiron Corporation Group b streptococcus vaccine
JP4697706B2 (en) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Polypeptide-vaccine for broad protection against highly virulent meningococcal strains
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2004230485B2 (en) 2003-04-10 2009-01-22 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
DE10327439A1 (en) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Imidazopyridazinon- and Imidazopyridonderivate, their preparation and their use as medicaments
MXPA05013260A (en) 2003-06-26 2006-03-09 Chiron Corp Immunogenic compositions for chlamydia trachomatis.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2181714A3 (en) 2004-09-22 2010-06-23 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
ES2616294T3 (en) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
EP1977009B1 (en) 2005-12-27 2016-08-17 Obetech, LLC Adipogenic adenoviruses as a biomarker for disease
WO2008019162A2 (en) 2006-01-18 2008-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
CA2642721A1 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
ES2536426T3 (en) * 2006-03-23 2015-05-25 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060188A1 (en) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Conjugation Method
SI2268618T1 (en) * 2008-03-03 2015-09-30 Novartis Ag Compounds and compositions as tlr activity modulators
JP5867952B2 (en) * 2009-06-10 2016-02-24 ノバルティス アーゲー Benzonaphthyridine-containing vaccine
CN102760226B (en) * 2011-04-29 2015-07-01 贵州师范大学 Solid square-based test paper objective item answer sheet locating method

Also Published As

Publication number Publication date
BR112012004696A2 (en) 2017-05-23
CA2772657C (en) 2015-11-24
HUE032323T2 (en) 2017-09-28
AU2010308524B2 (en) 2014-03-20
CY1119618T1 (en) 2018-04-04
EP2473508A1 (en) 2012-07-11
PT2473508T (en) 2017-05-29
WO2011049677A1 (en) 2011-04-28
JP5525614B2 (en) 2014-06-18
UY32874A (en) 2011-04-29
DK2473508T3 (en) 2017-06-06
HRP20170707T1 (en) 2017-07-14
PE11562012A1 (en) 2012-08-23
AU2010308524A1 (en) 2012-04-19
CN102712636A (en) 2012-10-03
US20110053893A1 (en) 2011-03-03
TW201113281A (en) 2011-04-16
US9045470B2 (en) 2015-06-02
JP2013503884A (en) 2013-02-04
PL2473508T3 (en) 2017-08-31
EA201200406A1 (en) 2012-09-28
JO3257B1 (en) 2018-09-16
EA020962B1 (en) 2015-03-31
AR078153A1 (en) 2011-10-19
CN102712636B (en) 2014-11-05
CA2772657A1 (en) 2011-04-28
TWI445708B (en) 2014-07-21
SI2473508T1 (en) 2017-07-31
US20150225432A1 (en) 2015-08-13
MX2012002654A (en) 2012-03-26
ES2627669T3 (en) 2017-07-31
EP2473508B1 (en) 2017-03-08
LT2473508T (en) 2017-06-12

Similar Documents

Publication Publication Date Title
AU2011336417B2 (en) Bromodomain inhibitors and uses thereof
EA201692167A1 (en) Modulators of toll-secondary receptors
SG175390A1 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2012013714A (en) Multivalent synthetic nanocarrier vaccines.
IL218084D0 (en) Compounds and compositions as protein kinase inhibitors
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
EA201370066A1 (en) Modulators of estrogen receptors and their application
CL2012002489A1 (en) Compounds derived naphtho-imidazole silyl; pharmaceutical composition; and their use to prevent or treat an infection by Hepatitis C virus.
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2007142755A3 (en) Purine analogs
PH12013502192A1 (en) Antibodies against human angiopoietin 2
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
BR112014030386A2 (en) compounds and compositions for modulating egfr activity
IL223783A (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2009089494A3 (en) Pharmaceutical compositions
CY1118347T1 (en) Synthetic glucopyranosyl lipid adjuvant and FORMATIONS vaccines that contain
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
IL200240D0 (en) Conjugates of synthetic tlr agonists and uses therefor
EA200901032A1 (en) Compounds and compositions as gpr119 activity modulators
EP3329965A3 (en) Dosing regimen of anti-alpha4beta7-antikörper
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
IN2012DN02661A (en) "fatty acid niacin conjugates and their uses"
IN2012DN00754A (en) "compounds as lysophosphatidic acid receptor antagonists"